853 ACTM-838: a microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs after IV dosing in T-cell excluded solid tumors

• Laura Glickman,
• Michele Ardolino,
• Haixing Kehoe,
• Alexandre Iannello,
• Keith Cheung,
• Bret Peterson,
• Marie Marotel,
• Sara Tribble,
• Hailey He,
• Jonathan Hodgins,
• Christopher Rae,
• Christopher Thanos

Affiliations

Laura Glickman

Aff1 grid.417411.6Aduro BioTech Berkeley CA USA

Michele Ardolino

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Haixing Kehoe

1Actym Therapeutics, Inc, Berkeley, CA, USA

Alexandre Iannello

1Actym Therapeutics, Inc, Berkeley, CA, USA

Keith Cheung

1Actym Therapeutics, Inc, Berkeley, CA, USA

Bret Peterson

1Actym Therapeutics, Inc, Berkeley, CA, USA

Marie Marotel

2University of Ottawa, OHRI, Ottawa, Canada

Sara Tribble

1Actym Therapeutics, Inc, Berkeley, CA, USA

Hailey He

1Actym Therapeutics, Inc, Berkeley, CA, USA

Jonathan Hodgins

2University of Ottawa, OHRI, Ottawa, Canada

Christopher Rae

1Actym Therapeutics, Inc, Berkeley, CA, USA

Christopher Thanos

1Actym Therapeutics, Inc, Berkeley, CA, USA